PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.89%
Negative net income growth while TRAW stands at 93.12%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
6.88%
Some D&A expansion while TRAW is negative at -50.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Both cut yoy SBC, with TRAW at -9.74%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-183.61%
Negative yoy working capital usage while TRAW is 26.57%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-219.11%
Both negative yoy AP, with TRAW at -78.17%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
200.00%
Growth well above TRAW's 87.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Both yoy CFO lines are negative, with TRAW at -16.48%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
33.33%
Debt repayment growth of 33.33% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-53.76%
Both yoy lines negative, with TRAW at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.